

HEMATOLOGIC MALIGNANCIES

LYMPH NODES AND LYMPHATIC STRUCTURES ABOVE AND BELOW THE DIAPHRAGM

Note: The most common terms are included in this table. For a more complete listing of lymph nodes, see **Appendix I**.

ABOVE THE DIAPHRAGM	BELOW THE DIAPHRAGM
Axillary	Celiac
Brachial (lateral axillary)	Colic
Buccal (buccinator)	Femoral (superficial, inguinal)
Cervical, NOS	Gastric
Epitrochlear	Hepatic
Facial	Ileocolic
Hilar (bronchopulmonary)	Iliac
Infraclavicular (subclavicular)	Inguinal
Internal jugular	Internal iliac (hypogastric)
Mastoid (post-/retro-auricular)	Mesenteric
Mediastinal	Obturator
Occipital	Pancreatic
Para/peritracheal	Para-aortic
Parasternal (internal mammary)	Peyer's patches
Parotid	Popliteal
Pectoral (anterior axillary)	Porta hepatis (portal)
Posterior triangle (spinal accessory)	Pyloric
Preauricular	Retroperitoneal
Prelaryngeal	Sacral
Retropharyngeal	Spleen
Scalene (inferior deep cervical)	Splenic (lineal)
Sublingual	
Submandibular (submaxillary)	
Submental	
Subscapular (posterior axillary)	
Supraclavicular (transverse cervical)	
Tonsil	
Thymus	
Waldeyer ring [ring of lymphoid tissue formed by the two palatine tonsils, the pharyngeal tonsil (adenoids) and the lingual tonsil]	

HEMATOLOGIC MALIGNANCIES

LYMPHOMA

9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9823, 9826-9827
(varying primary sites and histologies)

- C700-C729, C751-C753: 9690, 9719 (2018-2022 only) (See Note 2)

C000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 3, 9

See Summary Stage 2018 Manual, Appendix III for a detailed listing of primary site/histology combinations for this schema

Note 1: Sources used in the development of this chapter

- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (<https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (<https://seer.cancer.gov/tools/ssm/ssm2000/>)
- Collaborative Stage Data Collection System, version 02.05: <https://cancerstaging.org/cstage/Pages/default.aspx>
- Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.
- Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.

Note 2: Histologies moved to Brain, CNS, Intracranial Gland

- For the histologies listed below, these have moved to the Brain, CNS Other and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses.
- If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter
- 9690, 9719
 - C700, C710-C719: *Brain*
 - C701, C709, C720-C725, C728-C729: *CNS Other*
 - C751-C753: *Intracranial Gland*

Note 3: Other Summary Stage chapters with the listed histologies

- **Brain:** C700, C710-C719 (9680, 9699, 9702-9715)
- **CNS Other:** C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715)
- **Heme Retic:** 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809)
- **Intracranial Gland:** C751-C753 (9680, 9699, 9702-9715)
- **Lymphoma Ocular Adnexa:** C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930)
- **Primary Cutaneous Lymphoma:** C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas*

Note 4: Chapter includes the preferred terms based on the 2017 *WHO Classification of Haematopoietic and Lymphoid Tissues*

9590 Malignant lymphoma, NOS
9591 Non-Hodgkin lymphoma, NOS
9596 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma
9597 Primary cutaneous follicle centre lymphoma
9650 Classical Hodgkin lymphoma
9651 Lymphocyte-rich classic Hodgkin lymphoma
9652 Mixed cellularity classic Hodgkin lymphoma
9653 Lymphocyte-depleted classic Hodgkin lymphoma
9659 Nodular lymphocyte predominant Hodgkin lymphoma
9663 Nodular sclerosis classic Hodgkin lymphoma
9673 Mantle cell lymphoma
9678 Primary effusion lymphoma
9679 Primary mediastinal (thymic) large B-cell lymphoma
9680 Diffuse large B-cell lymphoma (DLBCL)
9687 Burkitt lymphoma
9688 T-cell/histiocyte-rich large B-cell lymphoma
9689 Splenic marginal zone lymphoma
9690 Follicular lymphoma (except C700-C729, C751-C753 for 1/1/2023+)
9691 Follicular lymphoma, grade 2
9695 Follicular lymphoma, grade 1
9698 Follicular lymphoma, grade 3
9699 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
9702 Peripheral T-cell lymphoma, NOS
9705 Angioimmunoblastic T-cell lymphoma
9708 Subcutaneous panniculitis-like T-cell lymphoma
9709 Primary cutaneous peripheral T-cell lymphomas
9712 Intravascular large B-cell lymphoma
9714 Anaplastic large cell lymphoma, ALK-positive
9715 Anaplastic large cell lymphoma, ALK-negative (2021+ only)

9716 Hepatosplenic T-cell lymphoma
 9717 Enteropathy-associated T-cell lymphoma
 9718 Primary cutaneous anaplastic large cell lymphoma
 9719 Extranodal NK/T-cell lymphoma, nasal type (except C700-C729, C751-C753 for 1/1/2023+)
 9725 Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)
 9726 Primary cutaneous gamma-delta T-cell lymphoma (2018-2020 only, see code 9687/3 for 2021+)
 9735 Plasmablastic lymphoma
 9737 ALK-positive large B-cell lymphoma
 9738 HHV8-positive DLBCL, NOS
 9766 Lymphomatoid granulomatosis grade 3 (2021+ only)
 9823 Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
 9826 Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)
 9827 Adult T-cell leukemia/lymphoma

Note 5: Lymph node involvement

- Any mention of the terms including fixed, matted, mass in the hilum, mediastinum, retroperitoneum, and/or mesentery, palpable, enlarged, shotty, lymphadenopathy are all regarded as involvement for lymphomas when determining appropriate code.

Note 6: Peripheral Blood or Bone Marrow

- If there is peripheral blood or bone marrow involvement, code 7.

Note 7: Splenic involvement

- Splenic involvement is based on splenomegaly and FDG-PET or CT scans that state diffuse uptake, solitary mass, miliary lesions, or enlargement of greater than 13 cm
 - A physician's statement of splenomegaly may be used
 - FDG uptake in the spleen that is not diffuse is not enough to code as splenic involvement

Note 8: Bilateral sites Code 7 for involvement of bilateral sites (i.e., breast, eye, kidney, etc.).

- Example:* Patient with extranodal non-Hodgkin's Lymphoma, involving bilateral choroids, (single focus both sites), and no lymph node involvement.
 - Code 7 for bilateral involvement of choroids (eye)

Note 9: Not applicable codes

- Codes 0, 3, and 4 are not applicable for this chapter.

SUMMARY STAGE

1 Localized only

Nodal Lymphomas

- Single lymph node region involved
- Involvement of multiple nodal chains in the SAME lymph node region

Extranodal Lymphomas

- Single extralymphatic site
 - WITHOUT nodal involvement (see code 2 for WITH nodal involvement)
- Multifocal involvement of one extralymphatic organ/site (EXCEPT multifocal lung involvement or any liver involvement, see code 7)
 - WITHOUT nodal involvement (see code 7 for WITH nodal involvement)

2 Regional by direct extension only

Bulky disease present

Nodal Lymphomas

- Two or more lymph node regions involved SAME side of diaphragm
- Contiguous extension between extralymphatic sites and regional nodes
 - WITH or WITHOUT involvement of other nodal regions on SAME side of diaphragm

Extranodal Lymphomas

- Localized involvement of a single extralymphatic organ/site
 - WITH involvement of its regional lymph node(s) OR
 - WITH involvement of other lymph node(s) on the SAME side of the diaphragm

7 Distant site(s)/lymph node(s) involved

- Distant involvement
 - Diffuse or disseminated involvement of ONE OR MORE extralymphatic organ(s)/site(s) WITH or WITHOUT nodal involvement
 - Involvement of isolated extralymphatic organ in absence of involvement of adjacent lymph nodes, but in conjunction with disease in distant sites
 - Involvement of lymph node regions on BOTH sides of the diaphragm WITH or WITHOUT spleen involvement

- Involvement of lymph node regions ABOVE the diaphragm WITH spleen involvement
- Multifocal involvement of one extralymphatic organ/site WITH nodal involvement
- Noncontiguous extralymphatic organ involvement in conjunction with nodal disease (two or more sites involved)
- Distant metastasis, NOS
 - Blood/peripheral blood
 - Bone marrow
 - Cerebrospinal fluid (CSF)
 - Liver
 - Lung (other than by direct extension in code 2)

9 Unknown if extension or metastasis

MYCOSIS FUNGOIDES

9700-9701 (C000-C809)

Note 1: Sources used in the development of this chapter

- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (<https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (<https://seer.cancer.gov/tools/ssm/ssm2000/>)
- Collaborative Stage Data Collection System, version 02.05: <https://cancerstaging.org/cstage/Pages/default.aspx>
- Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.

Note 2: Not applicable codes

- Code 0 is not applicable for this chapter.

Note 3: Lymph node involvement

- All lymph node (regional and distant) involvement is coded as regional lymph node involvement.

Note 4: Visceral involvement

- Visceral involvement is metastatic disease and should be questioned in the absence of node or blood involvement.

SUMMARY STAGE

1 Localized only (localized, NOS)

- MFCG Stage I
 - Less than 10% of skin surface, no tumors
 - Limited to patches, papules, or plaques
- MFCG Stage II
 - Greater than or equal to 10% of skin surface, no tumors
 - Generalized patches, papules, or plaques
- Not stated whether patches, papules, or plaques
 - % of body surface not stated, no tumors
 - Skin involvement, NOS: extent not stated, no tumors

2 Regional by direct extension only

- MFCG Stage III
 - Cutaneous tumor, size not stated
 - Generalized erythroderma (confluence of erythema)
 - (greater than 50% of body involved with diffuse redness)
 - One or more tumors equal to 1 cm or greater
 - Sezary syndrome
 - Skin lesion described as tumor less than 1 cm

3 Regional lymph node(s) involved only

- Both clinically enlarged palpable lymph node(s) (adenopathy) AND
 - pathologically positive nodes
- Clinically enlarged palpable lymph node(s) (adenopathy) AND
 - either pathologically negative nodes or no pathological statement
- No clinically enlarged palpable lymph node(s) (adenopathy) BUT
 - pathologically positive lymph node(s)
- Dutch grade 1-4 OR NCI LN 0-4
 - Clone positive, negative or unknown
- Regional lymph node(s), NOS
 - Lymph node(s), NOS

4 Regional by BOTH direct extension AND regional lymph node(s) involved

- Codes (2) + (3)

7 Distant site(s) involved

- Distant site(s) (including further contiguous extension)
 - MFCG Stage IV
 - Bone marrow
 - Involvement by at least one organ outside the skin, nodes, blood, or bone marrow
 - Liver
 - Spleen
 - Visceral (non-cutaneous, extranodal) involvement, pathologically confirmed
- Distant metastasis, NOS
 - Carcinomatosis

9 Unknown if extension or metastasis

PRIMARY CUTANEOUS LYMPHOMAS (EXCLUDING MF AND SS)

9597, 9680, 9708-9709, 9712, 9718-9719, 9726

C440, C442-C449, C510, C609, C632

C440 Skin of lip, NOS

C442 External ear

C443 Skin of other and unspecified parts of face

C444 Skin of scalp and neck

C445 Skin of trunk

C446 Skin of upper limb and shoulder

C447 Skin of lower limb and hip

C448 Overlapping lesion of skin

C449 Skin, NOS

C510 Labium majus

C609 Penis

C632 Scrotum, NOS

Note 1: Sources used in the development of this chapter

- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (<https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (<https://seer.cancer.gov/tools/ssm/ssm2000/>)
- Collaborative Stage Data Collection System, version 02.05: <https://cancerstaging.org/cstage/Pages/default.aspx>
- Chapter 81 *Primary Cutaneous Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.

Note 2: Not applicable codes

- Code 0 is not applicable for this chapter.

Note 3: Mycosis Fungoides

- See the *Mycosis Fungoides* chapter for Mycosis Fungoides (9700) and Sezary syndrome (9701).

Note 4: Chapter includes the preferred terms based on the 2017 *WHO Classification of Haematopoietic and Lymphoid Tissues*

- 9597 Primary cutaneous follicle center lymphoma
- 9680 Primary cutaneous diffuse large B-cell lymphoma, leg type
- 9708 Subcutaneous panniculitis-like T-cell lymphoma
- 9709 Primary cutaneous peripheral T-cell lymphomas

- 9712 Intravascular large B-cell lymphoma
- 9718 Primary cutaneous anaplastic large cell lymphoma
- 9719 Extranodal NK/T-cell lymphoma, nasal type
- 9726 Primary cutaneous gamma-delta t-cell lymphoma

Note 5: Peripheral blood or bone marrow involvement

- If there is peripheral blood or bone marrow involvement, code 7.

SUMMARY STAGE

1 Localized only

- Solitary lesion
- Solitary skin involvement

2 Regional by direct extension only

- Multiple lesions confined to one or two contiguous body regions
- Multiple lesions, NOS
- Regional skin involvement

3 Regional lymph node(s) involved only

- Central
- Peripheral node region that drains an area of current or prior skin involvement
- Regional lymph node(s), NOS
 - Lymph node(s), NOS

4 Regional by BOTH direct extension AND regional lymph node(s) involved

- Codes (2) + (3)

7 Distant site(s)/lymph node(s) involved

- Distant site(s) (including further contiguous extension)
 - Blood/peripheral blood
 - Bone marrow
 - Extracutaneous non-lymph node disease present
 - Generalized skin involvement
 - Multiple lesions confined to discontinuous body regions
 - Multiple lesions confined to three or more contiguous body regions

- Visceral (non-cutaneous) metastasis
- Distant lymph node(s), NOS
- Distant metastasis, NOS
 - Carcinomatosis
 - Distant metastasis WITH or WITHOUT distant lymph node(s)

9 Unknown if extension or metastasis

MYELOMA AND PLASMA CELL DISORDERS

9671 Lymphoplasmacytic lymphoma (except C441, C690, C695-C696)

- C700-C729, C751-C753 (2018-2022 only) (See Note 2)

9731 Plasmacytoma, NOS

9732 Plasma cell myeloma/multiple myeloma

9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)

9761 Waldenstrom Macroglobulinemia

Note 1: Sources used in the development of this chapter

- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (<https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (<https://seer.cancer.gov/tools/ssm/ssm2000/>)
- Collaborative Stage Data Collection System, version 02.05: <https://cancerstaging.org/cstage/Pages/default.aspx>
- Chapter 82 *Plasma Cell Myeloma and Plasma Cell Disorder*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.

Note 2: Histologies moved to Brain, CNS, Intracranial Gland

- For the histology listed below, this has moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses. If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter
- 9671
 - **Brain:** C700, C710-C719
 - **CNS Other:** C701, C709, C720-C725, C728-C729
 - **Intracranial Gland:** C751-C753

Note 3: Not applicable codes

- Codes 0, 2, and 4 are not applicable for this chapter.

Note 4: Definition of Plasma cell myeloma

- Plasma cell myeloma/multiple myeloma (9732) is a widely disseminated plasma cell neoplasm, characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. It is always coded to 7 for systemic involvement.

Note 5: Lymphoplasmacytic lymphoma

- Lymphoplasmacytic lymphoma (9671) and Waldenstrom Macroglobulinemia (9761) are now collected with the plasma cell disorders.
- These are systemic diseases and should always be coded 7.

SUMMARY STAGE

1 Localized only

- Single plasmacytoma occurring in bone (osseous or medullary) (9731)
 - WITH or WITHOUT soft tissue extension
- Single plasmacytoma, NOS (9734)
 - Single plasmacytoma occurring outside of bone (extraosseous or extramedullary) (9734)

3 Regional lymph node(s) involved only

- Extraosseous plasmacytomas only (9734)
 - Regional lymph node(s), NOS
 - Lymph node(s), NOS

7 Distant site(s)/lymph node(s) involved

- Lymphoplasmacytic lymphoma (9671)
- Plasma cell myeloma (9732)
 - Multiple myeloma
 - Myeloma, NOS
 - Multiple extraosseous or extramedullary plasmacytomas
 - Multiple osseous or medullary plasmacytomas
 - Multiple plasmacytomas, NOS
- Waldenstrom Macroglobulinemia (9761)

9 Unknown if extension or metastasis (applicable for 9731 and 9734 only)

HEMERETIC

9724, 9727, 9740-9742, 9749, 9762-9809, 9811-9820, 9831-9920, 9931-9993

- C700-C729, C751-C753 for 9749, 9766 (2018-2022 only) (See Note 2)

C000-C440, C442-C689, C691-C694, C698-C809: 9591 and Schema Discriminator 1: 1, 2

C000-C699, C739-C750, C754-C809: 9751, 9755-9759

C000-C440, C442-C689, C691-C694, C698-C809: 9930

Note 1: Sources used in the development of this chapter

- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (<https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (<https://seer.cancer.gov/tools/ssm/ssm2000/>)
- Collaborative Stage Data Collection System, version 02.05: <https://cancerstaging.org/cstage/Pages/default.aspx>
- Chapter 83 *Leukemia*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.

Note 2: Histologies moved to Brain, CNS, Intracranial Gland

- For the histologies and primary sites listed below, these have moved to the Brain, CNS Other, and Intracranial Gland Summary Stage chapters starting with 2023 diagnoses.
- If you have one of these cases for 2018-2022, then this is the appropriate chapter. If you have one of these cases diagnosed on January 1, 2023, forward, see the appropriate chapter
 - **9749, 9766**
 - **Brain:** C700, C710-C719
 - **CNS Other:** C701, C709, C720-C725, C728-C729
 - **Intracranial Gland:** C751-C753

Note 3: Other Summary Stage chapters with the listed histologies

- **Brain:** 9751, 9755-9759 (C700, C710-C719)
- **CNS Other:** 9751, 9755-9759 (C701, C709, C720-C725, C728-C729)
- **Intracranial Gland:** 9751, 9755-9759 (C751-C753)
- **Lymphoma:** 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809)
- **Lymphoma Ocular Adnexa:** 9930 (C441, C690, C695-C696)

Note 4: The following histologies can be localized (code 1), systemic (7) or unknown (9)

9740 Mast cell sarcoma
9749 Erdheim-Chester disease (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)
9751 Langerhans cell histiocytosis, disseminated (except C700-C729, C751-C753)
9755 Histiocytic sarcoma (except C700-C729, C751-C753)
9756 Langerhans cell sarcoma (except C700-C729, C751-C753)
9757 Interdigitating dendritic cell sarcoma (except C700-C729, C751-C753)
9758 Follicular dendritic cell sarcoma (except C700-C729, C751-C753)
9759 Fibroblastic reticular cell tumor (except C700-C729, C751-C753)
9766 Lymphomatoid granulomatosis, Grade 3 (2021+ only) (except C700-C729, C751-C753 for 1/1/2023+)
9930 Myeloid sarcoma (except C441, C690, C695-C696)
9971 Polymorphic PTLN (2018-2020 only, nonreportable as of 2021)

Note 5: Lymph node involvement

- For histologies listed in **Note 4**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.

Note 6: The following histologies are systemic (code 7)

9591 Splenic B-cell lymphoma/leukemia, unclassifiable (except C441, C690, C695-C696)
9724 Systemic EBV-positive T-cell lymphoma of childhood
9727 Blastic plasmacytoid dendritic cell neoplasm
9741 Systemic mastocytosis with an associated hematological neoplasm
9742 Mast cell leukemia
9762 Heavy chain diseases
9800 Leukemia, NOS
9801 Acute undifferentiated leukemia
9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); *BCR-ABL1*
9807 Mixed-phenotype acute leukemia with t(v;11q23.3); *KMT2A*-rearranged
9808 Mixed-phenotype acute leukemia, B/myeloid, NOS
9809 Mixed-phenotype acute leukemia, T/myeloid, NOS
9811 B-lymphoblastic leukemia/lymphoma, NOS
9812 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); *BCR-ABL1*
9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); *KMT2A*-rearranged
9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); *ETV6-RUNX1*
9815 B-lymphoblastic/lymphoma with hyperdiploidy
9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL)
9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); *IGH/IL3*
9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); *TCF3-PBX1*
9819 B-lymphoblastic/lymphoma, BCR-ABL1-like (2021+ only)
9820 Lymphoid leukemia, NOS
9831 T-cell large granular lymphocytic leukemia
9832 Prolymphocytic leukemia, NOS

9833 B-cell prolymphocytic leukemia
 9834 T-cell prolymphocytic leukemia
 9837 T-lymphoblastic leukemia/lymphoma
 9840 Pure erythroid leukemia
 9860 Myeloid leukemia, NOS
 9861 Acute myeloid leukemia, NOS
 9863 Chronic myeloid leukemia
 9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); *DEK-NUP214*
 9866 Acute promyelocytic leukemia with *PML-RARA*
 9867 Acute myelomonocytic leukemia
 9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); *RBM15-MKLI*
 9870 Acute basophilic leukemia
 9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*
 9872 Acute myeloid leukemia, minimal differentiation
 9873 Acute myeloid leukemia without maturation
 9874 Acute myeloid leukemia with maturation
 9875 Chronic myeloid leukemia, *BCR-ABL1*-positive
 9876 Atypical chronic myeloid leukemia *BCR-ABL1*-negative
 9877 Acute myeloid leukemia with mutated NPM1 (2021+ only)
 9878 Acute myeloid leukemia with biallelic mutation of CEBPA (2021+ only)
 9879 Acute myeloid leukemia with mutated RUNX1 (2021+ only)
 9891 Acute monoblastic and monocytic leukemia
 9895 Acute myeloid leukemia with myelodysplasia-related changes
 9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), *RUNX1-RUNX1T1*
 9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); *KMT2A-MLLT3*
 9898 Myeloid leukemia associated with Down Syndrome
 9910 Acute megakaryoblastic leukemia
 9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); *RBM15-MKLI*
 9912 Acute myeloid leukemia with *BCR-ABL1* (2021+ only)
 9920 Therapy-related myeloid neoplasms
 9931 Acute panmyelosis with myelofibrosis
 9940 Hairy cell leukemia
 9945 Chronic myelomonocytic leukemia, NOS
 9946 Juvenile myelomonocytic leukemia
 9948 Aggressive NK-cell leukemia
 9950 Polycythemia vera
 9961 Primary myelofibrosis
 9962 Essential thrombocythemia
 9963 Chronic neutrophilic leukemia
 9964 Chronic eosinophilic leukemia, NOS
 9965 Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement
 9966 Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement
 9967 Myeloid/lymphoid neoplasm with *FGFR1* rearrangement
 9968 Myeloid/lymphoid neoplasm with PCM1-JAK2 (2021+ only)
 9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable
 9980 Myelodysplastic syndrome with single lineage dysplasia

9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia
9983 Myelodysplastic syndrome with excess blasts
9985 Myelodysplastic syndrome with multilineage dysplasia
9986 Myelodysplastic syndrome with isolated del(5q)
9989 Myelodysplastic syndrome, unclassifiable
9991 Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)
9992 Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)
9993 Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+ only)

Note 7: Only staging system

- Summary Stage is the only applicable staging system for this site/histology/schema.

Note 8: Not applicable codes

- Codes 0, 2, 3, and 4 are not applicable for this chapter.

SUMMARY STAGE

1 Localized only

- Localized disease
- (Single/solitary/unifocal/isolated)
- See Notes 2 and 3

7 Distant site(s)/lymph node(s) involved

- Systemic disease
- See Note 5

9 Unknown if extension or metastasis